A percentage of patients affected by COVID-19 show an exaggerated inflammatory response with high levels of D-dimer, ferritin and IL-6, which is associated with a poor prognosis. However, these markers are not sufficiently accurate to identify a bad evolution, nor to indicate a good response to the drugs administered.

Therefore, we propose a study to monitor the levels of different inflammatory markers throughout the course of the disease, in order to identify good biomarkers of clinical progression of COVID-19.

Currently, it is known that the increase of D-dimer, ferritin and IL-6 is associated with a worsening of the COVID-19 patient's conditions. But these markers are not enough to predict clinical outcomes in COVID-19 patients.
On the other hand, several drugs have been postulated for the treatment of COVID-19 (hydroxychloroquine, dexamethasone, tozilizumab, anakinra, etc.), but there is not enough evidence about their clinical efficacy. And, in front a specific patient, there is no markers of therapeutic response.

For this reason, the main objective of this study is to identify biomarkers that allow to discriminate those patients who will have a poor clinical evolution and, therefore, will require greater follow-up. Likewise, the study of cytokine levels after the administration of a certain treatment will be useful for us to identify biomarkers of good therapeutic response.